Candel Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 37.94 million compared to USD 18.79 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 0.65 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.9 USD | +3.25% | +14.10% | +505.44% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+505.44% | 265M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023